Simergent

Executive Summary

Simergent is developing Archimedes, an affordable, automated peritoneal dialysis (PD) device for home use, targeting the significant unmet need in emerging economies such as Mexico, China, and India. Current home dialysis systems are often complex, carry high infection risks, and limit patient mobility, leading to poor adoption and quality of life. Archimedes aims to address these pain points with a design focused on safety, usability, and improved patient outcomes. By leveraging AI and machine learning, the device intends to simplify the dialysis process, reduce infection rates, and enhance mobility, making home PD more accessible and attractive to patients and healthcare providers alike. The company was founded in 2019 and is headquartered in San Francisco, with a clear focus on emerging markets where the burden of kidney disease is high and access to affordable dialysis is limited. While Simergent has not yet disclosed funding or specific development milestones, the Archimedes device represents a potential paradigm shift in home dialysis. If successful, the company could capture a significant share of the growing PD market in developing nations. However, Simergent is early-stage with no commercial products or regulatory approvals to date, and execution risks remain substantial. The company's progress will depend on achieving key technical and regulatory milestones.

Upcoming Catalysts (preview)

• Q4 2026Completion of First-in-Human Clinical Study40% success
• Q2 2027Regulatory Submission (CE Mark or FDA 510(k))30% success
• Q3 2026Strategic Partnership with Distributor in Target Market50% success